Quarterly Drug Testing for Water Systems

Summary#

HB-2, the proposed “Endocrine-Disrupting Pharmaceuticals Water Safety Act,” would amend Tennessee law on water quality and rulemaking. Its stated goal is to investigate possible risks from certain pharmaceuticals in water; that goal is not a guarantee of harm or of a particular health or environmental result. The bill is filed for introduction and is not law.

  • The Tennessee Department of Environment and Conservation (TDEC) must, within 180 days after the act takes effect, list pharmaceuticals that may enter waters and meet at least one of the bill’s criteria, then select three to five for further research and testing.
  • Each public water system and wastewater facility must test influent and effluent water every quarter for the selected pharmaceuticals and their active metabolites.
  • The tests must use department-approved methods and department-certified laboratories. Systems and facilities must report results to TDEC within 30 days of sampling.
  • TDEC must publish annual summaries of detected levels and, within 15 days of receiving certain positive results, begin research on possible effects on wildlife or human health and fertility.
  • The Tennessee Board of Water Quality, Oil and Gas must make rules for public water systems; the environment and conservation commissioner must make rules for wastewater facilities.

What it means for you#

  • Public water systems and wastewater facilities: Each would have to arrange quarterly testing, use approved methods and certified labs, and report results on time. The bill does not require them to remove the substances or meet a new contaminant limit.
  • Residents and water users: TDEC would publish annual summaries of detected levels. The bill does not set a drinking-water limit, require individual testing, or ban pharmaceuticals.
  • People researching or concerned about health and wildlife: TDEC must begin research after specified positive results. The bill names aquatic wildlife, children, and people of childbearing age as particular areas of concern, but does not set a deadline for completing the research.
  • Current requirements: The supplied material does not include the current versions of the amended laws, so I could not verify what testing or reporting rules already apply.

Money#

The bill requires testing, rulemaking, reporting, and research, but no cost estimate is available.

  • Public water systems and wastewater facilities would have to pay for or arrange quarterly laboratory testing; the bill does not say who ultimately bears those costs.
  • TDEC and other named state bodies would have work to do, but the bill gives no staffing or funding amount.
  • The bill sets no testing fees, fines, or new tax.

What is unclear#

  • The bill does not define how TDEC should decide which three to five pharmaceuticals “most merit” further investigation.
  • It does not set the testing methods, detection thresholds, or how results should be handled if methods differ.
  • It does not set a completion date, research method, or required outcome for the research.
  • It does not specify how testing and research will be funded, or how costs will be shared.
  • The supplied bill text does not explain how these duties would interact with existing water-quality rules.

Case for#

  • The bill appears intended to build evidence about pharmaceuticals that may enter water and could affect people or wildlife.
  • Quarterly testing could provide repeated measurements of selected substances in treated and untreated water.
  • Requiring research after positive results could help the state investigate possible effects rather than treating detection alone as proof of harm.

Case against#

  • Testing and laboratory requirements could impose costs on every public water system and wastewater facility, but the bill provides no cost estimate or funding plan.
  • TDEC must choose the substances and approved methods, but the bill gives few details for those decisions.
  • The bill requires research to begin after certain findings but does not set a deadline or say what action should follow from the research.
  • Testing and reporting may identify substances without requiring treatment or setting a safe level, so the bill does not itself ensure that detected substances will be reduced.